• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

VioQuest Pharmaceuticals to Present at the Cleveland Clinic's 4th Annual Medical Innovation Summit

Posted on: Monday, 6 November 2006, 12:01 CST

BASKING RIDGE, N.J., Nov. 6 /PRNewswire-FirstCall/ -- VioQuest Pharmaceuticals, Inc. (BULLETIN BOARD: VQPH) , a New Jersey-based biopharmaceutical company focused on acquiring, developing and commercializing targeted cancer compounds, announced that Mr. Daniel Greenleaf, President and CEO, has accepted an invitation to speak at the prestigious 2006 Medical Innovation Summit held by the Cleveland Clinic from November 6-8, 2006 at the InterContinental Hotel & Conference Center, 9801 Carnegie Avenue, Cleveland, Ohio 44106. Mr. Greenleaf will present at 4:15 on Tuesday, November 7th. This will be the second year that VioQuest is presenting.

Mr. Greenleaf will provide an overview of the Company and an update on its clinical development programs, including its two targeted cancer agents, VQD-001, currently in Phase I/IIa clinical trials for solid tumors, and VQD-002 in clinical trials for leukemia and solid tumors. Additionally, Mr. Greenleaf will discuss the upcoming NDA filing for leishmaniasis for VQD-001. Mr. Greenleaf will also discuss the plans for the Company's subsidiary Chiral Quest, which include continuing to seek alternative strategies, including a possible sale of that business.

The Medical Innovation Summit is attended by more than 800 top-level senior industry executives, entrepreneurs, venture capitalists and clinicians to focus on the medical, technological and economic trends reshaping the neuroscience market. Also featured will be the Cleveland Clinic's first-ever selection of the "Top 10" Healthcare Innovations for 2007; live, interactive surgeries and in-depth debates on industry challenges. For more information about the Medical Innovation Summit, please visit http://www.clevelandclinic.org/innovations/.

About VioQuest Pharmaceuticals, Inc.

VioQuest Pharmaceuticals, Inc. focuses on acquiring, developing, and commercializing targeted late preclinical and early clinical stage therapies with unique mechanisms of action for oncology, viral and autoimmune disorders. VioQuest has two targeted therapeutics in clinic trials: VQD-001, an inhibitor of specific protein tyrosine phosphatases, has shown compelling preclinical activity in both renal and melanoma cancers, and VQD-002 which inhibits the phosphorylation of Akt which can be seen in abnormal levels in breast, ovarian, colorectal, pancreatic, and liquid cancers. VioQuest's subsidiary Chiral Quest, Inc., a pioneer in asymmetric chemocatalysis and custom synthesis, offers its proprietary technology products to well-known pharmaceutical and fine chemical companies worldwide to improve their production efficiencies and, in some instances, to increase the overall safety and efficacy of the underlying drug.

Forward-Looking Statements

This press release contains forward-looking statements that involve risks and uncertainties that could cause VioQuest's actual results and experiences to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are often, but not always, made through the use of words or phrases such as anticipates, expects, plans, believes, intends, and similar words or phrases. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. Among other things, there can be no assurances that VioQuest will receive any proceeds in connection with a sale or other disposition of its Chiral Quest division, or that the FDA will approve VioQuest's planned NDA submission relating to VQD-001 for the treatment of leishmaniasis, and even if approved, there is no assurance that VioQuest will be able to successfully commercialize VQD-001 for the treatment of leishmaniasis or any other indication. Other risks and uncertainties include the possibility that the results of clinical trials will not support VioQuest's claims, the possibility that VioQuest's development efforts relating to its product candidates, including VQD-001 and VQD-002, will not be successful, the inability to obtain regulatory approval of VioQuest's product candidates, VioQuest's reliance on third-party researchers to develop its product candidates, its lack of experience in developing and commercializing pharmaceutical products, and the possibility that its licenses to develop and commercialize its product candidates may be terminated. Additional risks are described in VioQuest's Annual Report on Form 10-KSB for the year ended December 31, 2005. VioQuest assumes no obligation and does not intend to update these forward-looking statements, except as required by law

VioQuest Pharmaceuticals, Inc.: Noonan Russo: Diane Perry Investors: Vice President, Sharon Weinstein 212-845-4271 Corporate Communications & Media: Investor Relations Ben Carmichael 212-845-4242 908-766-4400 / 917-834-7526

VioQuest Pharmaceuticals, Inc.

CONTACT: Diane Perry, Vice President, Corporate Communications &Investor Relations of VioQuest Pharmaceuticals, Inc., +1-908-766-4400,+1-917-834-7526; or Investors - Sharon Weinstein, +1-212-845-4271, or Media -Ben Carmichael, +1-212-845-4242, both of Noonan Russo

Web site: http://www.clevelandclinic.org/innovations

Source: PRNewswire-FirstCall

More News in this Category